Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
November 23 2023 - 1:00AM
Geneva, Switzerland, November 23, 2023
- Addex Therapeutics (SIX and Nasdaq: ADXN), a
clinical-stage pharmaceutical company pioneering allosteric
modulation-based drug discovery and development, today announced
that that it will issue its Third Quarter 2023 Financial Results on
November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of
Discovery – Biology and Mikhail Kalinichev, Head of Translational
Science, will provide a business update and a review of the Addex
product pipeline during a teleconference and webcast for investors,
analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST)
the same day.
Title: Addex Therapeutics to Release
Third Quarter 2023 Financial Results and Provides Corporate Update
Date: November 29, 2023Time: 16:00 CET (15:00 GMT /
10:00 EST / 07:00 PST)
Joining the Conference
Call:
- Participants are required to
register in advance of the conference using the link provided
below. Upon registering, each participant will be provided with
Participant Dial-in numbers, and a unique Personal PIN.
- In the 10 minutes prior to the
call’s start time, participants will need to use the conference
access information provided in the e-mail received at the point of
registering. Participants may also use the call me feature instead
of dialing the nearest dial in number.
Online Registration:
https://register.vevent.com/register/BI3c9fae3a9f2f4f47a845f71e3c6922e6
Webcast URL: https://edge.media-server.com/mmc/p/dt7y766k
About Addex
Therapeutics: Addex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available,
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional, non-allosteric molecules
and may offer an improved therapeutic approach to conventional
“orthosteric” small molecule or biological drugs. Addex’s
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex’s lead drug candidate, ADX71149 (mGlu2 positive
allosteric modulator or PAM) is in a Phase 2 clinical trial for the
treatment of epilepsy. The company’s second clinical program,
dipraglurant (mGlu5 negative allosteric modulator or NAM), is under
evaluation for future development in post-stroke recovery. Indivior
PLC has licensed Addex’s GABAB PAM program for the development of
drug candidates, with a focus on substance use disorder. Addex is
also advancing a broad preclinical pipeline, which includes
development of a range of GABAB PAM for chronic cough, mGlu7 NAM
for stress related disorders, M4 PAM for schizophrenia and other
forms of psychosis and mGlu2 NAM for mild neurocognitive disorders
and depression. Addex shares are listed on the SIX Swiss Exchange
and American Depositary Shares representing its shares are listed
on the NASDAQ Capital Market, and trade under the ticker symbol
“ADXN” on each exchange.
Contacts:
Tim Dyer Chief Executive Officer Telephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike Sinclair Partner, Halsin Partners +44 (0)7968
022075 msinclair@halsin.com |
Addex Forward Looking
Statements:This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including statements about the
intended use of proceeds of the offering. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Addex Therapeutics’ Annual Report on Form 20-F for the year
ended December 31, 2022, as filed with the SEC on March 30, 2023,
the final prospectus supplement and accompanying prospectus and
other filings that Addex Therapeutics may make with the SEC in the
future. Any forward-looking statements contained in this press
release represent Addex Therapeutics’ views only as of the date
hereof and should not be relied upon as representing its views as
of any subsequent date. Addex Therapeutics explicitly disclaims any
obligation to update any forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Aug 2023 to Aug 2024